鶹ý represented BICO Group AB (“BICO”) in its agreement to sell MatTek Corp and Visikol Inc to Sartorius Lab Holding GmbH (“Sartorius”) for $80 million. The transaction follows BICO’s updated strategy to focus on lab automation and selected workflows, with proceeds from the sale used to strengthen BICO’s balance sheet and accelerate its growth agenda. The transaction is expected to close in Q2 2025.
MatTek is a market-leading provider of 3D microtissue models and primary cells for in-vitro testing, offering faster, more cost-efficient, and reproducible alternatives to animal testing. Visikol specializes in advanced imaging and digital pathology.
MatTek’s solutions enhance Sartorius’ Lab Products and Services division’s offerings of cell analysis instruments, reagents, and AI-supported data models. The combined portfolio will be one of the most comprehensive solutions on the market, enabling researchers to accelerate new therapy development and reduce animal testing.
The 鶹ý deal team was led by partners Christopher Bourne and Gabor Garai and included associates Graham MacEwan and Bayleigh Sauerwald.
